Is Revvity, Inc. overvalued or undervalued?

As of 18 June 2025, the valuation grade for Revvity, Inc. has moved from very expensive to expensive, indicating a slight improvement in perceived value but still reflecting significant overvaluation. The company is currently assessed as overvalued based on key financial ratios, including a P/E ratio of 33, an EV to EBITDA ratio of 15.29, and a PEG ratio of 3.05, all of which suggest that the stock is trading at a premium compared to its earnings growth potential.
In comparison to its peers, Hologic, Inc. has a more favorable P/E ratio of 21.10 and an EV to EBITDA of 14.37, while The Cooper Companies, Inc. shows a P/E of 33.85 and an EV to EBITDA of 14.70. These comparisons highlight that Revvity, Inc. is not only more expensive than its direct competitors but also underperforming in terms of returns, with a year-to-date decline of 14.93% compared to a modest 2.44% gain in the S&P 500. Overall, Revvity, Inc. appears to be overvalued in the current market landscape.